Browse Studies — Arctuva

Phase 1

Phase 1b Study of TMV Vaccine Therapy Alone and TMV Vaccine Plus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

This phase Ib trial tests the safety, side effects and best dose of tumor membrane vesicle (TMV) vaccine therapy alone and in combination with pembrolizumab an…

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell Carcinoma+20 more

Estimated

~$10 – $6,250

Emory UniversityNCT06868433

Phase 2

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Trial

This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resecta…

Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07465276

Phase 2

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)…

Metastatic MelanomaSquamous Cell Carcinoma of the Head and NeckNon-small Cell Lung Cancer

Estimated

~$10 – $8,750

Iovance Biotherapeutics, Inc.NCT03645928